Comerica Bank’s Acadia Pharmaceuticals ACAD Stock Holding History

Comerica Bank’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$850K	Sell	31,838 -4,810	-13%	-$115K	﹤0.01%	1608
2025 Q3	$782K	Sell	36,648 -7,335	-17%	-$173K	﹤0.01%	1671
2025 Q2	$949K	Buy	43,983 +883	+2%	+$16.4K	﹤0.01%	1561
2025 Q1	$716K	Buy	43,100 +42,215	+4,770%	+$767K	﹤0.01%	1674
2024 Q4	$16.2K	Buy	885 +169	+24%	+$2.73K	﹤0.01%	3081
2024 Q3	$11K	Buy	716 +199	+38%	+$3.32K	﹤0.01%	3166
2024 Q2	$8.4K	Sell	517 -427	-45%	-$6.89K	﹤0.01%	3200
2024 Q1	$17.5K	Sell	944 -41,353	-98%	-$1.02M	﹤0.01%	3063
2023 Q4	$1.32M	Buy	42,297 +41,861	+9,601%	+$1,000K	0.01%	1387
2023 Q3	$9.09K	Buy	+436	New	+$11.8K	﹤0.01%	3225
2020 Q2	–	Sell	-4,027	Closed	-$205K	–	2270
2020 Q1	$205K	Buy	+4,027	New	+$166K	﹤0.01%	2078
2018 Q4	–	Sell	-46,269	Closed	-$1.02M	–	2266
2018 Q3	$1.02M	Buy	+46,269	New	+$728K	0.01%	1585

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Comerica Bank's ACAD Position: Q4 2025 in Review

Comerica Bank reduced its Acadia Pharmaceuticals (ACAD) stake by 13% in Q4 2025, selling an estimated $115K and leaving 31,838 shares worth $850K. The position accounts for ﹤0.01% of the portfolio, ranked #1608.

Comerica Bank first reported a position in ACAD in Q3 2018 and has held it in 12 quarters since. The position peaked at $1.32M in Q4 2023. 335 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Comerica Bank held 31,838 shares of Acadia Pharmaceuticals worth $850K as of Q4 2025.
Comerica Bank sold 4,810 Acadia Pharmaceuticals shares in Q4 2025, an estimated $115K.
Acadia Pharmaceuticals made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #1608 holding.
Comerica Bank first reported a position in Acadia Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Comerica Bank's Acadia Pharmaceuticals position peaked at $1.32M in Q4 2023.
335 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.